Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

Update (June 23): The RECOVERY group posted the results of its study on dexamethasone to medRxiv on June 22. In a press release on Tuesday (June 16), researchers from a large, randomized controlled ...

Among patients hospitalized with COVID-19, particularly those who were also receiving noninvasive ventilation or invasive mechanical ventilation, dexamethasone was associated with reduced mortality.

The glucocorticoid dexamethasone (Dex) is widely used in preterm infants for the prevention of chronic lung disease. However, major concern has arisen about the long-term sequelae of this therapy.

Paris, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan.

Objective: To compare the efficacy and tolerability of dexamethasone-21-palmitate and mepivacaine alone and in combination in the acute treatment of facet syndrome. Results: In all three groups ...

The primary corticosteroid used to control cerebral edema is dexamethasone. More than 40 years ago, dexamethasone was used in patients with brain tumors, and it is still used today. Other steroids ...

Dexamethasone 0.5mg, 0.75mg, 4mg, 6mg; tabs. Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in ...

Dexamethasone phosphate (as sodium); 4mg/mL, 10mg/mL; soln for IV or IM inj; contains sulfites. Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens.

FRIDAY, Jan. 24, 2025 (HealthDay News) -- For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival ...